

Status: Currently Official on 14-Feb-2025
Official Date: Official as of 01-Nov-2020
Document Type: USP Monographs
DocId: GUID-4C532457-13FC-4E54-AEA2-56071EE3E95C_2_en-US
DOI: https://doi.org/10.31003/USPNF_M12135_02_01
DOI Ref: I44kk

© 2025 USPC
Do not distribute

Add the following:

▲Chlorambucil Compounded Oral Suspension

DEFINITION

Chlorambucil Compounded Oral Suspension contains NLT 90.0% and NMT 110.0% of the labeled amount of chlorambucil ($C_{14}H_{19}Cl_2NO_2$).

Prepare Chlorambucil Compounded Oral Suspension 2 mg/mL as follows (see [Pharmaceutical Compounding—Nonsterile Preparations \(795\)](#)).

Chlorambucil tablets, ^a equivalent to	200 mg of chlorambucil
Vehicle: a 1:1 mixture of Ora Plus ^b and Ora-Sweet, ^b a sufficient quantity to make	100 mL

^a Chlorambucil 2-mg tablets, GlaxoSmithKline, Research Triangle Park, NC.

^b Perrigo, Allegan, MI.

Place the *Chlorambucil tablets* into a suitable container and triturate to a fine powder. Add a small amount of *Vehicle* to form a smooth paste. Add a sufficient amount of *Vehicle* to make the contents pourable. Transfer contents stepwise and quantitatively to a calibrated container using the remainder of the *Vehicle*. Add sufficient *Vehicle* to bring to final volume. Shake to mix well.

ASSAY

• PROCEDURE

Solution A: 0.2% (v/v) glacial acetic acid in water

Mobile phase: Methanol and *Solution A* (65:35)

Standard solution: 0.2 mg/mL of [USP Chlorambucil RS](#) in methanol

Sample solution: Transfer 1.0 mL of Oral Suspension into a 10-mL volumetric flask, add methanol to volume, and filter. [NOTE—The *Standard solution* and the *Sample solution* must be used within 6 h of preparation.]

Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

Mode: LC

Detector: UV 258 nm

Column: 4.6-mm × 25-cm; 5-μm packing L1

Temperatures

Autosampler: 15°

Column: 40°

Flow rate: 2.0 mL/min

Injection volume: 25 μL

System suitability

Sample: *Standard solution*

[NOTE—The retention time for chlorambucil is about 3.6 min.]

Suitability requirements

Tailing factor: NMT 2.0

Relative standard deviation: NMT 2.0% for replicate injections

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of chlorambucil ($C_{14}H_{19}Cl_2NO_2$) in the portion of Oral Suspension taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of chlorambucil from the *Sample solution*

r_S = peak response of chlorambucil from the *Standard solution*

C_s = concentration of [USP Chlorambucil RS](#) in the *Standard solution* (mg/mL)

C_u = nominal concentration of chlorambucil in the *Sample solution* (mg/mL)

Acceptance criteria: 90.0%–110.0%

SPECIFIC TESTS

- **pH (791):** 3.5–4.5

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Package in tight, light-resistant containers. Store in a refrigerator.
 - **BEYOND-USE DATE:** NMT 14 days after the day on which it was compounded when stored in a refrigerator
 - **LABELING:** Label it to indicate that it is to be well-shaken before use, and to state the *Beyond-Use Date*.
 - **USP REFERENCE STANDARDS (11):**
[USP Chlorambucil RS](#)
- ▲ (USP 1-May-2020)

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
CHLORAMBUCIL COMPOUNDED ORAL SUSPENSION	Brian Serumaga Science Program Manager	CMP2020 Compounding 2020

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 44(5)

Current DocID: [GUID-4C532457-13FC-4E54-AEA2-56071EE3E95C_2_en-US](#)

DOI: https://doi.org/10.31003/USPNF_M12135_02_01

DOI ref: [l44kk](#)